These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37263977)

  • 1. High concordance of clone detection between peripheral blood and bone marrow by targeted next-generation sequencing-A pilot study in patients with MDS.
    Loacker L; Petzer V; Bachmann S; Griesmacher A; Wolf D; Stauder R
    Br J Haematol; 2023 Aug; 202(3):e16-e19. PubMed ID: 37263977
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines.
    Bräuninger A; Blau W; Kunze K; Desch AK; Brobeil A; Tur MK; Etschmann B; Günther U; Körholz D; Schliesser G; Käbisch A; Kiehl M; Rummel M; Gattenlöhner S
    J Mol Diagn; 2018 May; 20(3):344-354. PubMed ID: 29471115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome.
    Mohamedali AM; Alkhatabi H; Kulasekararaj A; Shinde S; Mian S; Malik F; Smith AE; Gäken J; Mufti GJ
    Blood; 2013 Jul; 122(4):567-70. PubMed ID: 23760614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
    Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
    Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.
    Lew JL; Fenderson JL; Carmichael MG
    Hawaii J Med Public Health; 2017 Nov; 76(11 Suppl 2):10-12. PubMed ID: 29164009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.
    Guo Y; Bosompem A; Mohan S; Erdogan B; Ye F; Vickers KC; Sheng Q; Zhao S; Li CI; Su PF; Jagasia M; Strickland SA; Griffiths EA; Kim AS
    BMC Genomics; 2015 Sep; 16():727. PubMed ID: 26400237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.
    Sakr R; Renneville A; Saada V; Cotteret S; Martin JE; Droin N; Selimoglu-Buet D; Besse B; Hollebecque A; Marzac C; Pasquier F; Micol JB; De Botton S; Mir O; Solary E; Willekens C
    Leuk Lymphoma; 2018 Jul; 59(7):1742-1745. PubMed ID: 29115897
    [No Abstract]   [Full Text] [Related]  

  • 9. Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing?
    Giagounidis A; Haase S
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):321-331. PubMed ID: 32089213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Getting personal with myelodysplastic syndromes: is now the right time?
    Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).
    Mohamedali AM; Gäken J; Ahmed M; Malik F; Smith AE; Best S; Mian S; Gaymes T; Ireland R; Kulasekararaj AG; Mufti GJ
    Leukemia; 2015 Sep; 29(9):1928-38. PubMed ID: 25943179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.
    Moyo TK; Savona MR
    Curr Hematol Malig Rep; 2016 Dec; 11(6):441-448. PubMed ID: 27734261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of next generation sequencing in myelodysplastic syndromes.
    Spaulding TP; Stockton SS; Savona MR
    Br J Haematol; 2020 Jan; 188(2):224-239. PubMed ID: 31571207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myelodysplastic syndromes: preleukemic syndromes].
    Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.
    Uy GL; Duncavage EJ; Chang GS; Jacoby MA; Miller CA; Shao J; Heath S; Elliott K; Reineck T; Fulton RS; Fronick CC; O'Laughlin M; Ganel L; Abboud CN; Cashen AF; DiPersio JF; Wilson RK; Link DC; Welch JS; Ley TJ; Graubert TA; Westervelt P; Walter MJ
    Leukemia; 2017 Apr; 31(4):872-881. PubMed ID: 27740633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient myelodysplastic syndrome associated with isochromosome 7q abnormality.
    Leung EW; Woodman RC; Roland B; Abdelhaleem M; Freedman MH; Dror Y
    Pediatr Hematol Oncol; 2003; 20(7):539-45. PubMed ID: 12959859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes.
    Radakovich N; Meggendorfer M; Malcovati L; Hilton CB; Sekeres MA; Shreve J; Rouphail Y; Walter W; Hutter S; Galli A; Pozzi S; Elena C; Padron E; Savona MR; Gerds AT; Mukherjee S; Nagata Y; Komrokji RS; Jha BK; Haferlach C; Maciejewski JP; Haferlach T; Nazha A
    Blood Adv; 2021 Nov; 5(21):4361-4369. PubMed ID: 34592765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.